Hayder Kadhim: Determinants and Outcomes of OAC Discontinuation in Atrial Fibrillation
Hayder Kadhim, Consultant Cardiologist at Region Östergötland, shared a post on LinkedIn:
”I am pleased and honored to present our latest study as a poster at the prestigious ESOC Conference in Maastricht.
Our research explores risk factors associated with oral anticoagulant (OAC) interruptions in patients with non-valvular atrial fibrillation (NVAF), including both temporary and permanent discontinuations.
We also examine treatment pattern changes across different OAC types and dosing strategies, and compare clinical outcomes between patients who persist with therapy and those who discontinue.
This work is based on high-quality Swedish national registers, including AURICULA, which uniquely enabled us to identify the exact dates of treatment discontinuation and generate robust real-world evidence.”
Stay updated with Hemostasis Today.
-
May 12, 2026, 16:46Tagreed Alkaltham: Why Apheresis Matters in Modern Transfusion Medicine
-
May 12, 2026, 16:37Reinhold Kreutz: Cardiovascular Burden in Acute Intermittent Porphyria Needs Greater Awareness
-
May 12, 2026, 16:33Pablo Corral: The Truth About Very Low LDL-Cholesterol
-
May 12, 2026, 16:24Mildred Lundgren: We Must Talk About the Invisible Causes of Stroke
-
May 12, 2026, 16:17Irene Scala: The Sex Disparities In Access to Acute Stroke Treatments In Italy
-
May 12, 2026, 16:04May Nour: UCLA Health Mobile Stroke Unit Becomes The 1st In The World to Perform mCTA In the Field
-
May 12, 2026, 15:57Leonardo Roever: Prognostic Impact of Lipoprotein(a) and CAR in Elderly Acute Ischemic Stroke Patients
-
May 12, 2026, 15:54Bruno Pougault: Prioritizing Laboratory Tests in Resource-Limited Emergency Care
-
May 12, 2026, 15:37Jennifer Holter Chakrabarty: Supporting the Next Generation of Hematology Researchers